All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What are the key considerations of the updated guidelines for early relapsed multiple myeloma?

Featured
May 23, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory MM

The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US. We asked, What are the key considerations of the updated guidelines for early relapsed multiple myeloma?

What are the key considerations of the updated guidelines for early relapsed multiple myeloma?

Kumar begins by defining the differences between early and late relapses in multiple myeloma. Kumar then references key considerations from the updated NCCN guidelines for multiple myeloma (https://jnccn.org/view/journals/jnccn/20/1/article-p8.xml), such as the use of 3-drug combinations rather than 2-drug combinations. Kumar also discusses the use of anti-CD38 antibodies, proteasome inhibitors, and immunomodulatory drugs in early relapsed multiple myeloma.

 

Share:

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox